Dr. Michael McKenzie joins Diamond CBD to provide guidance on the development of cannabinoid formulations

FT LAUDERDALE, FL–(Marketwired – Oct 12, 2017) – PotNetwork Holding Inc. (OTC: POTN) today announces that as part of its strategy to formulate, produce and market a spectrum of exclusive and illness-targeted cannabidiol (CBD) blends, the Company has appointed Dr. Michael McKenzie to the advisory board of its subsidiary, Diamond CBD, Inc.

Diamond CBD is assembling a team of diverse medical professionals with firsthand CBD knowledge and savvy regarding how these components can contribute to optimizing quality of life. As an industry-leading physician, Dr. McKenzie will offer guidance, resources and insight as PotNetwork mobilizes to serve the growing demand for premium medical-grade marijuana products.

“We are amassing a powerful team of professionals with unparalleled knowledge of medicine and the supplementary potential of CBD. We are seeking to be the leading contender in the CBD marketplace and now have the professional credibility for it,” states PotNetwork CEO Richard Goulding. “Dr. McKenzie is an incredible asset to our team. He has already provided valuable guidance based on his firsthand knowledge of real patients and experiences of cannabis compounds for the treatment of a wide array of illnesses.”

Filling a critical void between traditional pharmaceutical products and the untapped benefits of CBD, Dr. McKenzie has tailored his family practice — much to the benefit of his wide patient base. His willingness to not accept the status quo has allowed him to be a frontrunner in a bold new medical frontier. His reward has been overwhelming patient acceptance and response. 

“The impact of cannabinoid products has greatly improved the quality of life of many of my patients, in ways that I could never have accomplished utilizing pharmacy based products alone,” he says. “Being an integral part of this burgeoning new industry allows

Read More Here...